CAR-CIK (solid tumors)

  1. Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery Cancers (Basel). 2020 Aug; 12(8): 2175. Published online 2020 Aug 5. doi: 10.3390/cancers12082175
  2. Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection
    Mol Ther. 2021 Dec 1;29(12):3398-3409. doi: 10.1016/j.ymthe.2021.06.022. Epub 2021 Jul 2.
  3. Engineering CAR-T cells to activate small-molecule drugs in situ Nature Chemical Biology volume 18, pages216–225 (2022)
  4. Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPalpha checkpoint blocker Blood 2023

RNA-loaded Dendritic Cell Platform (CMN-001)

  1. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products.
    Vaccine. 2007 Sep 27;25 Suppl 2:B47-60. doi: 10.1016/j.vaccine.2007.06.006. Epub 2007 Jun 21.
  2. Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma.
    Clin Cancer Res. 2020 May 15;26(10):2327-2336. doi: 10.1158/1078-0432.CCR-19-2427. Epub 2020 Feb 7.
  3. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.
    Cancer. 2015 Apr 21;3:14. doi: 10.1186/s40425-015-0055-3. eCollection 2015.
  4. Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response.
    Mol Ther Nucleic Acids. 2013 May 7;2(5):e91. doi: 10.1038/mtna.2013.18.
  5. Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro.
    J Immunother. 2011 Jan;34(1):45-57. doi: 10.1097/CJI.0b013e3181fb651a.
  6. Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent.
    J Immunol. 2008 Oct 15;181(8):5296-305. doi: 10.4049/jimmunol.181.8.5296.
  7. Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response.
    J Immunother. 2008 Oct;31(8):731-41. doi: 10.1097/CJI.0b013e318183db02.
  8. Autologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer:
    The ADAPT Trial and Beyond Eur Urol Focus (2022), https://doi. org/10.1016/j.euf.2022.04.003